+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Induced Pluripotent Stem Cells Market

  • PDF Icon

    Report

  • 152 Pages
  • November 2024
  • Region: Global
  • BCC Research
  • ID: 6025094
Description Jump to:
The Induced Pluripotent Stem Cells Market was valued at USD 3.4 billion in 2023, and is projected to reach USD 5.2 billion by 2028, rising at a CAGR of 9.10%.

The rapid evolution of human iPSC technology since 2007 led to an exciting new age for the fields of disease modeling, drug discovery, stem cell biology and regenerative medicine. However, there are certain challenges associated with the use of iPSCs, including issues with clonal selection, in vitro culture, adaptability, and/or cell multiplication. Thus, even though the field of iPSCs has come a long way, there are still many issues that need to be seriously addressed to transform hope to reality regarding the effective clinical application of these cells in regenerative medicine.

Report Scope

This report summarizes the single-use technologies market, including a market snapshot and company profiles of key players. It provides a comprehensive market breakdown with in-depth information regarding each segment. The overview section of the report describes market trends and dynamics, including drivers, challenges and opportunities for the market. It provides information on emerging technologies and developments in the industry. It analyzes critical market players' financials, product portfolios and recent activities.

The report analyzes and makes projections for each market and its applications, along with forecasts for the next five years. The report also features profiles of leading companies in the biopharmaceutical single-use technologies industry, including Sartorius AG, Danaher Corp, Merck KGaA and Thermo Fisher Scientific Inc.

The market is segmented by geographical region into North America, Europe, Asia-Pacific and the Rest of the World (RoW). Regional analysis is further broken down by country as:
  • North America: The U.S., Canada and Mexico.
  • Europe: Germany, the U.K., France, Italy, Spain and the Rest of Europe.
  • Asia-Pacific: China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific.
Data for market estimates have been provided for 2021 and 2022 as the historical years, 2023 as the base year and forecast through 2029.

The report includes:

  • 220 data tables and 59 additional tables
  • An analysis of the global markets for single-use technologies for biopharmaceutical manufacturing
  • Analyses of global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
  • Estimates of the size and revenue prospects of the global market, along with a market share analysis by technology, single-use component, application, end user, and region/country
  • A look at recent technical advances in different sole-use technologies and bioreactors and the extent of adoption by commercial customers and regulatory authorities
  • Facts and figures pertaining to the market dynamics, technical advances, regulations, and the impact of region- and industry-specific macroeconomic variables
  • A Porter's Five Forces model, and global supply chain and PESTLE analyses
  • Patent activity and key patent grants/publications, along with an analysis of the impact of new developments in sole-use technologies and bioreactors for pharmaceuticals
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
  • Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook
  • Profiles of market leaders, including: Danaher Corp, Thermo Fisher Scientific Inc., Sartorius AG and Merck KGaA.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Introduction
  • Induced Pluripotent Stem Cells (iPSC) Generation
Chapter 3 Market Dynamics
  • Global Market Dynamics
  • Market Drivers
  • Increasing Prevalence of Chronic Diseases
  • Increasing Investment in Biotechnology Industry
  • Increasing Demand for Personalized Medicines
  • Increasing Investments for Drug Research and Development
  • Demand for Effective Drug Discovery and Development Process
  • Minimizing Animal Testing
  • Market Restraints
  • High Development Costs and Lack of Skilled Workforce
  • Challenges Associated with iPSC-based Disease Modeling, Cell Therapy and Drug Discovery
  • Market Opportunities
  • Technological Advances
  • Growth in iPSC Banking
Chapter 4 Emerging Technologies and Developments
  • Advances in the iPSC Research
  • Reprogramming Technologies
  • Gene Editing Technologies
  • 3D Organoids
  • Regenerative Medicine
  • Evolution and Current Application of Artificial Intelligence (AI) in iPSC Research
Chapter 5 Clinical Trial Analysis
  • Clinical Trials
Chapter 6 Patent Analysis
  • Patent Analysis
Chapter 7 Market Segmentation Analysis
  • Segmentation Breakdown
  • Overview
  • Generation of Induced Pluripotent Stem Cells -- Market Analysis, by Reprogramming Method
  • Market for Induced Pluripotent Stem Cells, by Generation Method
  • Market for Induced Pluripotent Stem Cells, by Application
  • Academic Research
  • Pharmaco-toxicological Screening
  • Drug Discovery and Development
  • Disease Modeling
  • Tissue Engineering
  • Cell Therapy
  • Global Market
  • Regional Markets for iPSCs, by Application
  • iPSC-derived Tissue Cell Market, by Type
  • Cardiomyocytes
  • Neurons
  • Endothelial Cells
  • Hepatocytes
  • Other Cells
  • iPSC-derived Tissue Cell Market, by Species
  • Global Market
  • iPSC-derived Tissue Cell Market, by Application
  • Global Market
  • Market for Induced Pluripotent Stem Cells, by Product Function
  • Global Market
  • Regional Markets for iPSCs, by Product Function
  • Market for Induced Pluripotent Stem Cells, by End Use
  • Induced Pluripotent Stem Cell Contract Service Types
  • Major Players
  • Global Market
  • Geographic Breakdown
  • Market for Induced Pluripotent Stem Cells, by Region
  • The U.S.
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 8 Competitive Intelligence
  • Competitive Landscape -- Overview
  • Strategic Analysis
  • Agreements
  • Collaborations & Strategic Alliances
  • Partnerships
  • New Product Development and Launches
  • Expansions and Acquisitions
  • Fund Raising
  • Approval and Clinical Trials
  • Others
  • Major Companies in Induced Pluripotent Stem Cells Market, by Type of Offerings
Chapter 9 Appendix
  • Methodology
  • Abbreviations
  • Sources
  • Company Profiles
  • ATCC
  • AXOL BIOSCIENCE LTD.
  • BIO-TECHNE
  • FUJIFILM CELLULAR DYNAMICS INC.
  • LONZA
  • MERCK KGAA
  • NCARDIA
  • QIAGEN
  • REPROCELL INC.
  • STEMCELL TECHNOLOGIES
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table: Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
Table 1: Projected Number of Adults 50 Years and Older with =1 Chronic Condition in the United States, 2020-2050
Table 2: The U.S. NIH Funding for Various Disease Conditions, 2019-2025
Table 3: Brief Information on iPSC Repositories
Table 4: Induced Pluripotent Stem Cells Pipeline, 2023
Table 5: List of Selected Patents Published on iPSC Technology, 2021
Table 6: List of Selected Patents Published on iPSC Technology, 2022
Table 7: List of Selected Patents Published on iPSC Technology, 2023
Table 8: List of Selected Patents Published on iPSC Technology, Till August 2024
Table 9: Summary of Different Reprogramming Methods
Table 10: Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
Table 11: Global Market for Induced Pluripotent Stem Cells, by Method, Through 2028
Table 12: Selected Interventional Clinical Trials of iPSC-based Cell Therapy
Table 13: Global Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 14: The U.S. Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 15: European Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 16: Asia-Pacific Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 17: RoW Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 18: Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, Through 2028
Table 19: Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Species, Through 2028
Table 20: Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Application, Through 2028
Table 21: Global Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 22: The U.S. Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 23: European Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 24: Asia-Pacific Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 25: RoW Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 26: Global Market for Induced Pluripotent Stem Cells, by End Use, Through 2028
Table 27: Major Companies Providing iPSC Contract Services, by State/Country
Table 28: Global Market for Induced Pluripotent Stem Cell Contract Services, by Region, Through 2028
Table 29: Global Market for Induced Pluripotent Stem Cells, by Region, Through 2028
Table 30: The U.S. Market for Induced Pluripotent Stem Cells, by State, Through 2028
Table 31: European Market for Induced Pluripotent Stem Cells, by Country, Through 2028
Table 32: Asia-Pacific Market for Induced Pluripotent Stem Cells, by Country, Through 2028
Table 33: Agreements: Induced Pluripotent Stem Cells Market, 2019-2024
Table 34: Collaborations and Strategic Alliances: Induced Pluripotent Stem Cells Market, 2019-2024
Table 35: Partnerships: Induced Pluripotent Stem Cells Market, 2020-2023
Table 36: New Product Development and Launches: Induced Pluripotent Stem Cells Market, 2020-2023
Table 37: Expansions and Acquisitions: Induced Pluripotent Stem Cells Market, 2020-2023
Table 38: Fund Raising: Induced Pluripotent Stem Cells Market, 2020-2024
Table 39: Approvals and Clinical Trials: Induced Pluripotent Stem Cells Market, 2020-2024
Table 40: Other Competitive Strategies: Induced Pluripotent Stem Cells Market, 2020-2024
Table 41: Major Companies in the Induced Pluripotent Stem Cells Market
Table 42: Glossary of Terms Used in This Report
Table 43: Report Information Sources
Table 44: ATCC: Company Snapshot
Table 45: ATCC: Product Portfolio
Table 46: ATCC: News/Key Developments, 2023 and 2024
Table 47: Axol Bioscience Ltd.: Company Snapshot
Table 48: Axol Bioscience Ltd.: Product Portfolio
Table 49: Axol Bioscience Ltd.: News/Key Developments, 2021-2024
Table 50: Bio-Techne: Company Snapshot
Table 51: Bio-Techne: Financial Performance, FY 2022 and 2023
Table 52: Bio-Techne: Product Portfolio
Table 53: Bio-Techne: News/Key Developments, 2021-2023
Table 54: Fujifilm Cellular Dynamics Inc.: Company Snapshot
Table 55: Fujifilm Cellular Dynamics Inc.: Product Portfolio
Table 56: Fujifilm Cellular Dynamics Inc.: News/Key Developments, 2021-2023
Table 57: Lonza: Company Snapshot
Table 58: Lonza: Financial Performance, FY 2022 and 2023
Table 59: Lonza: Product Portfolio
Table 60: Lonza: News/Key Developments, 2020
Table 61: Merck KGaA: Company Snapshot
Table 62: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 63: Merck KGaA.: Product Portfolio
Table 64: Merck KGaA: News/Key Developments, 2021-2024
Table 65: Ncardia: Company Snapshot
Table 66: Ncardia: Product Portfolio
Table 67: Ncardia: News/Key Developments, 2021-2024
Table 68: Qiagen: Company Snapshot
Table 69: Qiagen: Financial Performance, FY 2022 and 2023
Table 70: Qiagen: Product Portfolio
Table 71: REPROCELL Inc.: Company Snapshot
Table 72: REPROCELL Inc.: Product Portfolio
Table 73: REPROCELL Inc.: News/Key Developments, 2021-2024
Table 74: STEMCELL Technologies.: Company Snapshot
Table 75: STEMCELL Technologies: Product Portfolio
Table 76: STEMCELL Technologies: News/Key Developments, 2021-2022
Table 77: Takara Bio Inc.: Company Snapshot
Table 78: Takara Bio Inc.: Financial Performance, FY 2022 and 2023
Table 79: Taraka Bio Inc.: Product Portfolio
Table 80: Thermo Fisher Scientific Inc.: Company Snapshot
Table 81: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 82: Thermo Fisher Scientific Inc.: Product Portfolio
Table 83: Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024
List of Figures
Summary Figure: Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, 2020-2028
Figure 1: Methodology for the Generation of Induced Pluripotent Stem Cells
Figure 2: Snapshot of the Market Dynamics for iPSCs
Figure 3: Venture Averages for Biopharma Therapeutics and Platform Companies, 2010-2024
Figure 4: Personalized Medicines Contribution in Total FDA Approvals, 2015-2023
Figure 5: Global Pharmaceutical R&D Spending, by Select Country/Region, 2010-2022
Figure 6: Phases of the Pharmaceutical Industry Research and Development Process
Figure 7: iPSC-derived Organoids Used for Drug Screening
Figure 8: Temporal Distribution of Studies Using ESCs, iPSCs, Somatic Cell Nuclear Transfer (SCNT) Cells and Parthenotic PSCs (pPSCs), Jan 1, 2011-Dec 13, 2022
Figure 9: Clinical-trial Analysis: Induced Pluripotent Stem Cells, as of August 2024
Figure 10: Number of Patents Documented Over Time on iPSC Technology, 2010-2024
Figure 11: Number of Granted Patents Documents on iPSC Technology, by Country, 2021-2024
Figure 12: PubMed Citations and Human iPSC Lines Registered in hPSCreg and EBiSC, 2007-2022
Figure 13: Published Applications of hiPSC Technology from Top 20 Pharma Companies, 2010-2020
Figure 14: Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, 2020-2028
Figure 15: Global Market Shares of Induced Pluripotent Stem Cells, by Reprogramming Method, 2022
Figure 16: Global Market for Induced Pluripotent Stem Cells, by Method, 2020-2028
Figure 17: Global Market Shares of Induced Pluripotent Stem Cells, by Method, 2022
Figure 18: Utility of hiPSCs to Humanize Drug Discovery
Figure 19: Autologous and Allogeneic iPSC-Based Cell Therapy
Figure 20: Global Market for Induced Pluripotent Stem Cells, by Application, 2020-2028
Figure 21: Global Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 22: The U.S. Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 23: European Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 24: Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 25: RoW Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 26: Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2020-2028
Figure 27: Global Market Shares of Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2022
Figure 28: Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Species, 2020-2028
Figure 29: Global Market Shares of Induced Pluripotent Stem Cell-derived Tissue Cells, by Application, 2022
Figure 30: Global Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 31: The U.S. Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 32: European Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 33: Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 34: RoW Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 35: Global Market Shares of Induced Pluripotent Stem Cells, by End Use, 2022
Figure 36: Global Market Shares of Induced Pluripotent Stem Cell Contract Services, by Region, 2022
Figure 37: Global Market Shares of Induced Pluripotent Stem Cells, by Region, 2022
Figure 38: NIH Spending on Induced Pluripotent Stem Cell Research in the U.S., 2015-2023
Figure 39: The U.S. Market Shares of Induced Pluripotent Stem Cells, by State, 2022
Figure 40: European Market Shares of Induced Pluripotent Stem Cells, by Country, 2028
Figure 41: Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Country, 2022
Figure 42: Global Market Shares of Induced Pluripotent Stem Cells, by Key Strategies Adopted, 2019-2024
Figure 43: Bio-Techne: Revenue Share, by Business Unit, FY 2023
Figure 44: Bio-Techne: Revenue Share, by Country/Region, FY 2023
Figure 45: Lonza: Revenue Share, by Business Unit, FY 2023
Figure 46: Lonza: Revenue Share, by Country/Region, FY 2023
Figure 47: Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 48: Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 49: Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 50: Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 51: Takara Bio Inc.: Revenue Share, by Business Unit, FY 2023
Figure 52: Takara Bio Inc.: Revenue Share, by Country/Region, FY 2023
Figure 53: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023

Companies Mentioned

  • ATCC
  • Axol Bioscience Ltd.
  • Bio-Techne
  • Fujifilm Cellular Dynamics Inc.
  • Lonza
  • Merck KGaA
  • Ncardia
  • Qiagen
  • Reprocell Inc.
  • Stemcell Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages152
PublishedNovember 2024
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 3.4 Billion
Forecasted Market Value ( USD ) by 2028 $ 5.2 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024 - Product Image

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Induced Pluripotent Stem Cell (iPSC) - Global Strategic Business Report - Product Image

Induced Pluripotent Stem Cell (iPSC) - Global Strategic Business Report

  • Report
  • 349 Pages
  • Global
From
Induced Pluripotent Stem Cells - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Induced Pluripotent Stem Cells - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 110 Pages
  • Global
From
Induced Pluripotent Stem Cells Market by Derived Cell Type, by Application, by End-User, and By Region - Product Image

Induced Pluripotent Stem Cells Market by Derived Cell Type, by Application, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application (Regenerative Medicine), By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application (Regenerative Medicine), By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From

About the iPS Cell Market

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments. The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting. Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.